Stock Track | Edwards Lifesciences Soars 5.4% on Strong Q4 Revenue Growth and Positive Outlook

Stock Track

Feb 12, 2025

Edwards Lifesciences Corporation (EW) stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.

A key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 million for the full year 2024. This segment, which includes the PASCAL and EVOQUE systems, is expected to continue driving growth, with the company forecasting TMTT sales in the range of $500 million to $530 million for 2025.

While the company's flagship Transcatheter Aortic Valve Replacement (TAVR) segment experienced slower growth, with sales increasing 6% year-over-year to $4.1 billion in 2024, Edwards Lifesciences remains optimistic about the segment's prospects. The company cited compelling early TAVR data that could lead to more patients seeking treatment, positioning the segment for multi-year growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1176850411"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1176850411\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1176850411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-12 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1176850411","market":"us","top_or_hot":-1,"title":"Stock Track | Edwards Lifesciences Soars 5.4% on Strong Q4 Revenue Growth and Positive Outlook","media":"Stock Track","content":"<p>Edwards Lifesciences Corporation (EW) stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.</p>\n\n<p>A key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 million for the full year 2024. This segment, which includes the PASCAL and EVOQUE systems, is expected to continue driving growth, with the company forecasting TMTT sales in the range of $500 million to $530 million for 2025.</p>\n\n<p>While the company's flagship Transcatheter Aortic Valve Replacement (TAVR) segment experienced slower growth, with sales increasing 6% year-over-year to $4.1 billion in 2024, Edwards Lifesciences remains optimistic about the segment's prospects. The company cited compelling early TAVR data that could lead to more patients seeking treatment, positioning the segment for multi-year growth.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Edwards Lifesciences Soars 5.4% on Strong Q4 Revenue Growth and Positive Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Edwards Lifesciences Soars 5.4% on Strong Q4 Revenue Growth and Positive Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-12 22:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Edwards Lifesciences Corporation (EW) stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.</p>\n\n<p>A key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 million for the full year 2024. This segment, which includes the PASCAL and EVOQUE systems, is expected to continue driving growth, with the company forecasting TMTT sales in the range of $500 million to $530 million for 2025.</p>\n\n<p>While the company's flagship Transcatheter Aortic Valve Replacement (TAVR) segment experienced slower growth, with sales increasing 6% year-over-year to $4.1 billion in 2024, Edwards Lifesciences remains optimistic about the segment's prospects. The company cited compelling early TAVR data that could lead to more patients seeking treatment, positioning the segment for multi-year growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"","article_id":"1176850411","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1176850411","pubTimestamp":1739370971,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Edwards Lifesciences Corporation  stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies  segment.A key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 mi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"股票跟踪Edwards Lifesciences因第四季度收入强劲增长和积极前景而飙升5.4%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"Edwards Lifesciences Corporation (EW) stock surged 5.4% in pre-market trading on Wednesday, driven by the company's impressive fourth quarter 2024 financial results and positive outlook for 2025. The medical device maker reported a 9% year-over-year increase in total sales to $1.39 billion for Q4 2024, fueled by robust growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) segment.\nA key highlight was the strong performance of the TMTT business, which saw sales jump 77% year-over-year to $352 million for the full year 2024. This segment, which includes the PASCAL and EVOQUE systems, is expected to continue driving growth, with the company forecasting TMTT sales in the range of $500 million to $530 million for 2025.\nWhile the company's flagship Transcatheter Aortic Valve Replacement (TAVR) segment experienced slower growth, with sales increasing 6% year-over-year to $4.1 billion in 2024, Edwards Lifesciences remains optimistic about the segment's prospects. The company cited compelling early TAVR data that could lead to more patients seeking treatment, positioning the segment for multi-year growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}